Hikma Pharmaceutical (HKMPF) 27.4000 $HKMPF
Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
PRWeb - Tue Dec 31, 2:11AM CST
Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
Research and Markets: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
Business Wire - Fri Dec 20, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g4ddq8/injectable) has announced the addition of the "Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013" report to their offering.
Injectable Generic & Biosimilar Drugs Market 2013 Analysis
M2 - Thu Dec 19, 4:53AM CST
The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical Industries. But interest in generic injectables has not been limited to established generic companies, as pharmaceutical majors like Pfizer have also become attracted to the market.
Unilife Signs Long-Term Supply Agreement with Hikma to Enhance Delivery of Generic Injectables
PR Newswire - Wed Nov 20, 8:00AM CST
Unilife Corporation ("Unilife"
(NASDAQ: UNIS, ASX: UNS) today announced the signing of a long-term commercial supply contract with Hikma Pharmaceuticals PLC ("Hikma" (LSE: HIK) for the use of Unifill® prefilled syringes with a range of generic injectable drugs.
Hikma Takes its Corporate Reporting to the Next Level With CRedit360 Sustainability Software
PR Newswire Europe - Wed Nov 20, 4:31AM CST
AMMAN, Jordan, November 20, 2013 /PRNewswire/ --
Biosimilars in Emerging Markets
M2 - Tue Jul 09, 3:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5tv4/biosimilars_in) has announced the addition of the "Biosimilars in Emerging Markets" report to their offering. There are few areas of the pharmaceutical market more hotly debated than biosimilars yet the pathway to developing a viable global product marketplace is not clear. Biosimilar interest is being driven by the potential offered by a range of high-value brands which will be subject to patent challenges in the next 5-10 years such as Roche's Herceptin and Avastin. The US market remains the big prize for biosimilars but is stalled with an untried regulatory process. Europe is more advanced but there are significant barriers to entry. It is no surprise, then, that biosimilar developers are turning to emerging markets as a preferred market entry point. The fundamentals of biosimilars in emerging markets are sound: high unmet clinical need in large and expanding populations, growing GDP and health spending, increasing patient expecta
Healthcare, Regulatory and Reimbursement Landscape - Jordan
M2 - Mon Jan 21, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/rk36wm/healthcare) has announced the addition of GlobalData's new report "Healthcare, Regulatory and Reimbursement Landscape - Jordan" to their offering. The report is an essential source of information and provides an analysis of the healthcare, regulatory and reimbursement landscape of Jordan. The report identifies the key trends in the healthcare market of Jordan. The report also provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Jordan. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by Our team of industry experts. Jordan has a small population, approximately 6.2 million in 2011. However, the population of Jordan is increasing due to a high birth rate and low mortality rate, along with an in
Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
PRWeb - Tue Dec 31, 2:11AM CST
Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
Research and Markets: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013
Business Wire - Fri Dec 20, 4:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/g4ddq8/injectable) has announced the addition of the "Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013" report to their offering.
Injectable Generic & Biosimilar Drugs Market 2013 Analysis
M2 - Thu Dec 19, 4:53AM CST
The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical Industries. But interest in generic injectables has not been limited to established generic companies, as pharmaceutical majors like Pfizer have also become attracted to the market.
Unilife Signs Long-Term Supply Agreement with Hikma to Enhance Delivery of Generic Injectables
PR Newswire - Wed Nov 20, 8:00AM CST
Unilife Corporation ("Unilife"
(NASDAQ: UNIS, ASX: UNS) today announced the signing of a long-term commercial supply contract with Hikma Pharmaceuticals PLC ("Hikma" (LSE: HIK) for the use of Unifill® prefilled syringes with a range of generic injectable drugs. Hikma Takes its Corporate Reporting to the Next Level With CRedit360 Sustainability Software
PR Newswire Europe - Wed Nov 20, 4:31AM CST
AMMAN, Jordan, November 20, 2013 /PRNewswire/ --
Biosimilars in Emerging Markets
M2 - Tue Jul 09, 3:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5tv4/biosimilars_in) has announced the addition of the "Biosimilars in Emerging Markets" report to their offering. There are few areas of the pharmaceutical market more hotly debated than biosimilars yet the pathway to developing a viable global product marketplace is not clear. Biosimilar interest is being driven by the potential offered by a range of high-value brands which will be subject to patent challenges in the next 5-10 years such as Roche's Herceptin and Avastin. The US market remains the big prize for biosimilars but is stalled with an untried regulatory process. Europe is more advanced but there are significant barriers to entry. It is no surprise, then, that biosimilar developers are turning to emerging markets as a preferred market entry point. The fundamentals of biosimilars in emerging markets are sound: high unmet clinical need in large and expanding populations, growing GDP and health spending, increasing patient expecta
Healthcare, Regulatory and Reimbursement Landscape - Jordan
M2 - Mon Jan 21, 5:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/rk36wm/healthcare) has announced the addition of GlobalData's new report "Healthcare, Regulatory and Reimbursement Landscape - Jordan" to their offering. The report is an essential source of information and provides an analysis of the healthcare, regulatory and reimbursement landscape of Jordan. The report identifies the key trends in the healthcare market of Jordan. The report also provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Jordan. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by Our team of industry experts. Jordan has a small population, approximately 6.2 million in 2011. However, the population of Jordan is increasing due to a high birth rate and low mortality rate, along with an in
